Business Wire - Orexigen® Therapeutics Announces That Contrave® May Reverse the Incidence of Metabolic Syndrome
Shows Potential to Reduce Risks for Diabetes and Heart Disease
SAN FRANCISCO & SAN DIEGO — Orexigen([R]) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that based on a review of data from its Contrave([R]) Phase IIb trial, patients assigned to Contrave dosage groups demonstrated a 50% reduction in the prevalence of metabolic syndrome. Metabolic syndrome is a group of risk factors associated with obesity that may increase the risk of developing diabetes or cardiovascular disease. According to the American Heart Association, metabolic syndrome affects an estimated 47 million Americans.
Related Results
Smoking cessation drug may be helpful for nicotine addiction in schizophrenics.
Steady-state clinical pharmacokinetics of bupropion extended-release in youth…
Sporting Digest: drugs in sport
BCMA Calls for Tobacco Tax to Fund Stop-Smoking Programs.
Biovail Announces Receipt Of An Approvable Letter For Wellbutrin XL.
Orexigen conducted a retrospective evaluation on the baseline prevalence of metabolic syndrome, as it is defined by the Adult Treatment Panel (ATP) III Guidelines. The data revealed that among Contrave patients who completed 24 weeks of treatment, the percentage of subjects with metabolic syndrome decreased from 31% to 15% (p
